Immunoglobulin E specific for Phleum pratense pollen allergens (Phl p-specific IgE)

Immunoglobulin E (IgE) antibodies specific for Phleum pratense (Timothy grass) pollen allergens are the primary mediators of seasonal allergic reactions to grass pollen. These antibodies are produced by B cells upon sensitization and subsequently bind with high affinity to FcεRI receptors on the surface of mast cells and basophils [Gould & Sutton, 2008]. When an individual is re-exposed to Timothy grass allergens, such as the major allergens Phl p 1 and Phl p 5, these proteins cross-link the receptor-bound IgE molecules. This cross-linking triggers an intracellular signaling cascade leading to the rapid degranulation of the effector cells and the release of pro-inflammatory mediators like histamine and leukotrienes [Valenta et al., 2011]. These mediators are responsible for the clinical symptoms of allergic rhinitis, conjunctivitis, and asthma. In the context of therapeutic intervention, these specific IgE molecules represent a critical point of control for managing allergic diseases. Monoclonal antibodies like omalizumab target the Fc region of IgE, preventing it from binding to its receptors and effectively lowering the sensitivity of mast cells and basophils [NCBI, 2023]. Additionally, allergen-specific immunotherapy (AIT) utilizes Phleum pratense extracts to desensitize the immune system, often resulting in a decrease in specific IgE levels and an increase in protective IgG4 antibodies [Bousquet et al., 2012]. Understanding the dynamics of these antibodies is essential for the diagnosis and treatment of grass pollen-induced allergic conditions.

Other names

Timothy grass pollen-specific IgEAnti-Phl p IgEPhleum pratense-specific IgEGrass pollen-specific IgE

Omalizumab binds to the Cε3 domain of free IgE, preventing its interaction with the high-affinity FcεRI receptor on mast cells and basophils [NCBI, 2023]. Allergen immunotherapy (AIT) using Timothy grass pollen extracts induces T-cell tolerance and promotes the production of allergen-specific IgG4, which acts as a blocking antibody to prevent IgE-mediated mast cell activation [PubMed, 2011].